Development of a prognostic model based on an immunogenomic landscape analysis of medulloblastoma
Open Access
- 7 January 2021
- journal article
- research article
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 41 (1)
Abstract
Medulloblastoma (MB) is one of the most common central nervous system tumors in children. At present, the vital role of immune abnormalities has been proved in tumorigenesis and progression. However, the immune mechanism in MB is still poorly understood. In the present study, 51 differentially expressed immune-related genes (DE-IRGs) and 226 survival associated immune-related genes (Sur-IRGs) were screened by an integrated analysis of multi-array. Moreover, the potential pathways were enriched by functional analysis, such as ‘cytokine–cytokine receptor interaction’, ‘Ras signaling pathway’, ‘PI3K-Akt signaling pathway’ and ‘pathways in cancer’. Furthermore, 10 core IRGs were identified from DE-IRGs and Sur-IRGs. And the potential regulatory mechanisms of core IRGs were also explored. Additionally, a new prognostic model, including 7 genes (HDGF, CSK, PNOC, S100A13, RORB, FPR1, and ICAM2) based on IRGs, was established by multivariable COX analysis. In summary, our study revealed the underlying immune mechanism of MB. Moreover, we developed a prognostic model associated with clinical characteristics and could reflect the infiltration of immune cells.Keywords
This publication has 75 references indexed in Scilit:
- Inflammatory Mediators Influence the Expression of Nociceptin and Its Receptor in Human Whole Blood CulturesPLOS ONE, 2013
- EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancerMolecular Cancer, 2012
- Increased Microglia/Macrophage Gene Expression in a Subset of Adult and Pediatric AstrocytomasPLOS ONE, 2012
- Pediatric brainstem gangliogliomas show overexpression of neuropeptide prepronociceptin (PNOC) by microarray and immunohistochemistryPediatric Blood & Cancer, 2012
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II StudyJournal of Clinical Oncology, 2012
- Use of Allogeneic NK Cells for Cancer ImmunotherapyImmunotherapy, 2011
- Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsNature Reviews Cancer, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- S100A13 is a new angiogenic marker in human melanomaLaboratory Investigation, 2010
- International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) FamilyPharmacological Reviews, 2009